AHA Scientific Sessions

Scientific Sessions is the American Heart Association's largest gathering of scientists and healthcare professionals devoted to the science of cardiovascular disease and stroke and the care of patients suffering from these diseases. Programming is designed to improve patient care by communicating the most timely and significant advances in prevention, diagnosis and treatment of cardiovascular disease from many different perspectives.

Sessions provides five days of comprehensive, unparalleled education through more than 4,000 presentations given by some of the world's top leaders in the areas of cardiovascular disease as well as a chance to experience more than 300 exhibitors showcasing the latest cardiovascular technology and resources.

Find the latest #AHA12 Science News, Videos and Discussions on the AHA-PON Scientific Sessions page.

Latest Posts

CS.04: Randomized Comparison of the Effects of Two Doses of Dabigatran Etexilate on Clinical Outcomes Over 4.3 Years: Results of the Rely-able Double-blind Randomized Trial

CS.04: Clinical Science: Special Reports: Valvular Heart Disease, PAD, Atrial Fibrillation: International Perspectives

Stuart J Connolly,
McMaster Univ, Hamilton, ON, Canada

Randomized Comparison of the Effects of Two Doses of Dabigatran Etexilate on Clinical Outcomes Over 4.3 Years: Results of the Rely-able Double-blind Randomized Trial

Presentation Audio | Discussant Audio

Posted by PON Editor on Nov 9, 2012 9:17 AM CST

LBCT.06: MADIT Randomized Trial to Reduce Inappropriate Therapy (MADIT-RIT)

LBCT.06: Management of LV Dysfunction: Devices and Drugs

Arthur J. Moss
Univ of Rochester Medical Ctr, Rochester, NY

MADIT Randomized Trial to Reduce Inappropriate Therapy (MADIT-RIT)

Presentation Audio | Discussant Audio

Posted by PON Editor on Nov 9, 2012 9:01 AM CST

CS.04: Clinical Implications of Device-Detected Atrial Tachyarrhythmias: Results from the Registry of Atrial Tachycardia and Atrial Fibrillation Episodes in the Cardiac Rhythm Management Device Population (RATE)

CS.04: Clinical Science: Special Reports: Valvular Heart Disease, PAD, Atrial Fibrillation: International Perspectives

Steven Swiryn,
Northwestern Univ, Chicago, IL

Clinical Implications of Device-Detected Atrial Tachyarrhythmias: Results from the Registry of Atrial Tachycardia and Atrial Fibrillation Episodes in the Cardiac Rhythm Management Device Population (RATE)

Presentation Audio | Discussant Audio

Posted by PON Editor on Nov 8, 2012 12:14 PM CST

CS.04: Antithrombotic Treatments and Associated Outcomes in Patients with Atrial Fibrillation: The Global Anticoagulant Registry in the FIELD (GARFIELD)

CS.04: Clinical Science: Special Reports: Valvular Heart Disease, PAD, Atrial Fibrillation: International Perspectives

Ajay K Kakkar,
Thrombosis Res Inst, London, United Kingdom

Antithrombotic Treatments and Associated Outcomes in Patients with Atrial Fibrillation: The Global Anticoagulant Registry in the FIELD (GARFIELD)

Presentation Audio

Posted by PON Editor on Nov 8, 2012 12:11 PM CST

CS.04: Management and One Year Outcome of Atrial Fibrillation in Middle Eastern Cohort Enrolled in the Observational Gulf Survey of Atrial Fibrillation Events (Gulf SAFE)

CS.04: Clinical Science: Special Reports: Valvular Heart Disease, PAD, Atrial Fibrillation: International Perspectives

Mohammad Zubaid,
Faculty of Med, Kuwait Univ, Kuwait City, Kuwait

Management and One Year Outcome of Atrial Fibrillation in Middle Eastern Cohort Enrolled in the Observational Gulf Survey of Atrial Fibrillation Events (Gulf SAFE)

Presentation Audio

Posted by PON Editor on Nov 8, 2012 12:05 PM CST

CS.04: EndOVascular Treatment for Infra-inguinal Vessel, in Patients With Critical Limb Sichemia (olive) Registry in Japan

CS.04: Clinical Science: Special Reports: Valvular Heart Disease, PAD, Atrial Fibrillation: International Perspectives

Masato Nakamura,
Toho Univ, Ohashi medical Ctr, Tokyo, Japan

EndOVascular Treatment for Infra-inguinal Vessel, in Patients With Critical Limb Sichemia (OLIVE) Registry in Japan

Presenation Audio | Discussant Audio

Posted by PON Editor on Nov 8, 2012 11:42 AM CST

LBCT.06: The RELAXin in Acute Heart Failure (RELAX-AHF) Trial

LBCT.06: Management of LV Dysfunction: Devices and Drugs

John R Teerlink
San Francisco VAMC UCSF
San Francisco, CA

The RELAXin in Acute Heart Failure (RELAX-AHF) Trial

Presentation Audio | Discussant Audio

Posted by PON Editor on Nov 7, 2012 2:34 PM CST

CS.03: Impact of LX4211, a Dual Inhibitor of Sodium Glucose Transporter 1 and 2 on Cardiovascular Risk Factors in Type 2 Diabetes

CS.03: Clinical Science: Special Reports: Emerging Therapeutics for Diabetes and Dyslipidemia

Julio Rosenstock,
Dallas Diabetes and Endocrine Ctr., Dallas, TX

Impact of LX4211, a Dual Inhibitor of Sodium Glucose Transporter 1 and 2 on Cardiovascular Risk Factors in Type 2 Diabetes

Presentation Audio | Discussant Audio

Posted by PON Editor on Nov 7, 2012 2:25 PM CST

CS.03: Efficacy and Safety of a Fully Human Monoclonal Antibody Against PCSK9 as Monotherapy for Hypercholesterolemia: Results from the MENDEL Study, a Global Phase 2 Trial of AMG 145

CS.03: Clinical Science: Special Reports: Emerging Therapeutics for Diabetes and Dyslipidemia

Michael J. Koren,
Jacksonville Ctr for Clinical Res, Jacksonville, FL

Efficacy and Safety of a Fully Human Monoclonal Antibody Against PCSK9 as Monotherapy for Hypercholesterolemia: Results from the MENDEL Study, a Global Phase 2 Trial of AMG 145

Presentation Audio

Posted by PON Editor on Nov 7, 2012 1:31 PM CST

CS.03: AMG 145, a Fully Human Monoclonal Antibody Against Proprotein Convertase Subtilisin Kexin type 9 (PCSK9), Facilitates Achievement of NCEP LDL-Cholesterol Goals in High-Risk Patients

CS.03: Clinical Science: Special Reports: Emerging Therapeutics for Diabetes and Dyslipidemia

Nihar R. Desai,
TIMI Study Group, Div of Cardiovascular Med, Brigham and Women's Hosp, Boston, MA

AMG 145, a Fully Human Monoclonal Antibody Against Proprotein Convertase Subtilisin Kexin type 9 (PCSK9), Facilitates Achievement of NCEP LDL-Cholesterol Goals in High-Risk Patients

Presentation Audio

Posted by PON Editor on Nov 7, 2012 1:10 PM CST